Indivior Acquires Opiant Pharmaceuticals

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge in $2.2B CNS Biopharma “Merger of Equals”

August 6, 2026

Healthcare Services

Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive agreement to merge in a tax-free all-stock “merger of equals” transaction expected to create a diversified central nervous system biopharmaceutical leader. Under the deal, Supernus shareholders will receive 1.5401 Indivior shares per Supernus share, and Indivior shareholders will receive a $1.0 billion special cash dividend immediately prior to closing.

Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal

April 26, 2026

Healthcare Services

Sun Pharmaceutical Industries (Sun Pharma) entered into a definitive agreement to acquire all outstanding shares of Organon for $14.00 per share in an all-cash transaction valuing Organon at an enterprise value of $11.75 billion. The deal is expected to close in early 2027, subject to customary regulatory approvals and Organon stockholder approval.

Grünenthal Acquires Valinor Pharma for Approximately $250M

July 22, 2024

Pharmaceuticals

Grünenthal has acquired Chicago-based Valinor Pharma, including global rights to Movantik (naloxegol), in a transaction valued at about $250 million. The deal strengthens Grünenthal's U.S. footprint and adds an established pain-management product to its portfolio after Valinor scaled Movantik sales using Apollo Care's commercial and patient-access solutions.

Cooper Consumer Health Acquires Viatris' Over-the-Counter Business

July 3, 2024

Pharmaceuticals

Cooper Consumer Health has completed the acquisition of the Over-the-Counter (OTC) business of Viatris Inc., following regulatory approvals and worker council consultations. The deal brings more than 200 brands (including Betadine, Saugella, Armolipid and CB12), two manufacturing sites in Mérignac (France) and Confienza (Italy) and an R&D centre in Monza (Italy) into Cooper's platform, doubling Cooper's revenues to approximately €1.2bn.

Incyte Acquires Escient Pharmaceuticals

April 23, 2024

Biotechnology

Incyte has agreed to acquire Escient Pharmaceuticals for $750 million plus Escient's net cash, adding two first‑in‑class oral MRGPR antagonists (EP262 and EP547) to its inflammation and autoimmunity portfolio. The acquisition, subject to customary closing conditions and HSR clearance, expands Incyte's pipeline in dermatology, chronic urticaria and pruritus with expected closing in 3Q 2024.

Oragenics Acquires Odyssey Health Neurological Drug Assets

January 2, 2024

Pharmaceuticals

Oragenics, Inc. completed the acquisition of Odyssey Health, Inc.'s neurological drug therapy assets, including ONP-002, ONP-001 rights, a proprietary intranasal delivery device and related formulations. Odyssey retained its remaining assets and operations; Michael Redmond (former Odyssey CEO) was named President of Oragenics to oversee integration and advancement of the neurology pipeline as Oragenics prepares for Phase 2 studies of ONP-002.